Founders Capital Management - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2024. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Founders Capital Management ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2024$7,978
-32.6%
8,0000.0%0.01%
-37.5%
Q1 2024$11,840
+35.8%
8,0000.0%0.01%
+33.3%
Q4 2023$8,720
-7.6%
8,0000.0%0.01%
-14.3%
Q3 2023$9,440
-16.3%
8,0000.0%0.01%
-12.5%
Q2 2023$11,280
+93900.0%
8,0000.0%0.01%
-11.1%
Q1 2023$12
+33.3%
8,0000.0%0.01%
+28.6%
Q4 2022$9
-99.9%
8,0000.0%0.01%0.0%
Q3 2022$9,000
-30.8%
8,0000.0%0.01%
-30.0%
Q2 2022$13,000
-35.0%
8,0000.0%0.01%
-23.1%
Q1 2022$20,0000.0%8,0000.0%0.01%0.0%
Q4 2021$20,000
+53.8%
8,000
+61.0%
0.01%
+44.4%
Q3 2021$13,000
-7.1%
4,9700.0%0.01%0.0%
Q2 2021$14,000
+16.7%
4,9700.0%0.01%0.0%
Q1 2021$12,000
+33.3%
4,9700.0%0.01%
+50.0%
Q4 2020$9,000
+125.0%
4,9700.0%0.01%
+50.0%
Q1 2020$4,0000.0%4,9700.0%0.00%
+33.3%
Q4 2019$4,000
-20.0%
4,9700.0%0.00%
-25.0%
Q3 2019$5,0004,9700.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2024
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders